Does the media refer more to IBRX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than ImmunityBio. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Alnylam Pharmaceuticals' score of 0.09 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, BIIB or IBRX?

Biogen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.39 $1.29B $5.65 40.16 ImmunityBio $113.29M 81.06 -$351.40M -$0.97 N/A

Is BIIB or IBRX more profitable?

Biogen has a net margin of 8.32% compared to ImmunityBio's net margin of -598.55%. Biogen's return on equity of 11.18% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% ImmunityBio -598.55% N/A -51.65%

Does the media prefer BIIB or IBRX?

In the previous week, Biogen had 9 more articles in the media than ImmunityBio. MarketBeat recorded 15 mentions for Biogen and 6 mentions for ImmunityBio. Biogen's average media sentiment score of 0.76 beat ImmunityBio's score of 0.56 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or IBRX?

In the previous week, Roivant Sciences had 6 more articles in the media than ImmunityBio. MarketBeat recorded 12 mentions for Roivant Sciences and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Roivant Sciences' score of 0.37 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IBRX or INSM?

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 81.06 -$351.40M -$0.97 N/A Insmed $606.42M 42.86 -$1.28B -$4.11 N/A

Is IBRX or INSM more profitable?

Insmed has a net margin of -76.94% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Insmed -76.94% -123.94% -44.30%

Does the media favor IBRX or INSM?

In the previous week, Insmed had 4 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for Insmed and 6 mentions for ImmunityBio. Insmed's average media sentiment score of 0.66 beat ImmunityBio's score of 0.56 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INCY or IBRX?

Incyte has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.93 $1.29B $7.85 15.91 ImmunityBio $113.29M 81.06 -$351.40M -$0.97 N/A

Is INCY or IBRX more profitable?

Incyte has a net margin of 27.71% compared to ImmunityBio's net margin of -598.55%. Incyte's return on equity of 29.93% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% ImmunityBio -598.55% N/A -51.65%

Does the media refer more to INCY or IBRX?

In the previous week, Incyte had 16 more articles in the media than ImmunityBio. MarketBeat recorded 22 mentions for Incyte and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Incyte's score of 0.45 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 8 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

ImmunityBio (IBRX) Competitors

$8.64 -0.66 (-7.05%)

Closing price 03:59 PM Eastern

Extended Trading

$8.68 +0.04 (+0.46%)

As of 04:15 PM Eastern

Compare

IBRX vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy ImmunityBio stock or one of its competitors? ImmunityBio's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImmunityBio compare to Alnylam Pharmaceuticals?

ImmunityBio (NASDAQ:IBRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 63.88%. Alnylam Pharmaceuticals has a consensus price target of $367.20, suggesting a potential upside of 49.22%. Given ImmunityBio's higher possible upside, equities analysts plainly believe ImmunityBio is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87

Alnylam Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	81.06	-$351.40M	-$0.97	N/A
Alnylam Pharmaceuticals	$3.71B	8.87	$313.75M	$5.38	45.74

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than ImmunityBio. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Alnylam Pharmaceuticals' score of 0.09 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to ImmunityBio's net margin of -598.55%. Alnylam Pharmaceuticals' return on equity of 84.93% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

ImmunityBio has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats ImmunityBio on 13 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Biogen?

Biogen (NASDAQ:BIIB) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Biogen currently has a consensus target price of $230.14, indicating a potential upside of 1.43%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 63.88%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

87.9% of Biogen shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Biogen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.39	$1.29B	$5.65	40.16
ImmunityBio	$113.29M	81.06	-$351.40M	-$0.97	N/A

In the previous week, Biogen had 9 more articles in the media than ImmunityBio. MarketBeat recorded 15 mentions for Biogen and 6 mentions for ImmunityBio. Biogen's average media sentiment score of 0.76 beat ImmunityBio's score of 0.56 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to ImmunityBio's net margin of -598.55%. Biogen's return on equity of 11.18% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
ImmunityBio	-598.55%	N/A	-51.65%

Summary

Biogen beats ImmunityBio on 13 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than ImmunityBio. Roivant Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,257.35	-$299.77M	-$0.53	N/A
ImmunityBio	$113.29M	81.06	-$351.40M	-$0.97	N/A

Roivant Sciences currently has a consensus target price of $45.64, suggesting a potential upside of 22.52%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 63.88%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Roivant Sciences had 6 more articles in the media than ImmunityBio. MarketBeat recorded 12 mentions for Roivant Sciences and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Roivant Sciences' score of 0.37 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImmunityBio has a net margin of -598.55% compared to Roivant Sciences' net margin of -3,534.96%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
ImmunityBio	-598.55%	N/A	-51.65%

Summary

Roivant Sciences beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Insmed?

ImmunityBio (NASDAQ:IBRX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 63.88%. Insmed has a consensus price target of $204.91, suggesting a potential upside of 72.16%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

In the previous week, Insmed had 4 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for Insmed and 6 mentions for ImmunityBio. Insmed's average media sentiment score of 0.66 beat ImmunityBio's score of 0.56 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	81.06	-$351.40M	-$0.97	N/A
Insmed	$606.42M	42.86	-$1.28B	-$4.11	N/A

Insmed has a net margin of -76.94% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Insmed beats ImmunityBio on 10 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Incyte?

Incyte (NASDAQ:INCY) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

97.0% of Incyte shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Incyte presently has a consensus target price of $124.05, indicating a potential downside of 0.70%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 63.88%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Incyte has a net margin of 27.71% compared to ImmunityBio's net margin of -598.55%. Incyte's return on equity of 29.93% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
ImmunityBio	-598.55%	N/A	-51.65%

Incyte has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.93	$1.29B	$7.85	15.91
ImmunityBio	$113.29M	81.06	-$351.40M	-$0.97	N/A

In the previous week, Incyte had 16 more articles in the media than ImmunityBio. MarketBeat recorded 22 mentions for Incyte and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.56 beat Incyte's score of 0.45 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmunityBio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summary

Incyte beats ImmunityBio on 12 of the 17 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBRX vs. The Competition

Export

Metric	ImmunityBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.16B	$3.90B	$7.20B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-8.91	14.43	274.96	25.73
Price / Sales	81.06	1,372.47	644.74	85.68
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	-16.99	15.27	10.44	6.31
Net Income	-$351.40M	-$22.82M	$3.49B	$359.73M
7 Day Performance	9.54%	-0.15%	0.62%	1.52%
1 Month Performance	11.23%	-5.95%	-3.26%	-3.52%
1 Year Performance	234.56%	34.90%	16.28%	5.72%

ImmunityBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBRX ImmunityBio	2.3988 of 5 stars	$8.64 -7.1%	$14.20 +64.4%	+247.9%	$9.15B	$113.29M	N/A	691
ALNY Alnylam Pharmaceuticals	4.2152 of 5 stars	$241.25 +1.3%	$367.20 +52.2%	-45.2%	$32.28B	$4.80B	44.84	2,770	Analyst Forecast
BIIB Biogen	2.7537 of 5 stars	$217.19 +0.5%	$230.14 +6.0%	+60.2%	$32.09B	$10.03B	38.44	7,500
ROIV Roivant Sciences	3.065 of 5 stars	$39.92 +1.1%	$40.63 +1.8%	+155.8%	$28.83B	$8.26M	N/A	721
INSM Insmed	3.2104 of 5 stars	$122.98 +2.6%	$204.91 +66.6%	-16.7%	$26.86B	$606.42M	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBRX) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Competitors

IBRX vs. ALNY, BIIB, ROIV, INSM, and INCY

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Summary

How does ImmunityBio compare to Biogen?

Summary

How does ImmunityBio compare to Roivant Sciences?

Summary

How does ImmunityBio compare to Insmed?

Summary

How does ImmunityBio compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Competitors

IBRX vs. ALNY, BIIB, ROIV, INSM, and INCY

How does ImmunityBio compare to Alnylam Pharmaceuticals?

Do analysts prefer IBRX or ALNY?

Which has preferable earnings and valuation, IBRX or ALNY?

Does the media refer more to IBRX or ALNY?

Is IBRX or ALNY more profitable?

Which has more risk and volatility, IBRX or ALNY?

Do insiders & institutionals hold more shares of IBRX or ALNY?

Summary

How does ImmunityBio compare to Biogen?

Do analysts rate BIIB or IBRX?

Do institutionals & insiders believe in BIIB or IBRX?

Which has more risk & volatility, BIIB or IBRX?

Which has stronger earnings and valuation, BIIB or IBRX?

Does the media prefer BIIB or IBRX?

Is BIIB or IBRX more profitable?

Summary

How does ImmunityBio compare to Roivant Sciences?

Which has more risk & volatility, ROIV or IBRX?

Which has preferable earnings & valuation, ROIV or IBRX?

Do analysts recommend ROIV or IBRX?

Does the media favor ROIV or IBRX?

Do institutionals and insiders hold more shares of ROIV or IBRX?

Is ROIV or IBRX more profitable?

Summary

How does ImmunityBio compare to Insmed?

Do analysts rate IBRX or INSM?

Do institutionals and insiders hold more shares of IBRX or INSM?

Which has more risk and volatility, IBRX or INSM?

Does the media favor IBRX or INSM?

Which has stronger earnings and valuation, IBRX or INSM?

Is IBRX or INSM more profitable?

Summary

How does ImmunityBio compare to Incyte?

Do insiders and institutionals believe in INCY or IBRX?

Do analysts recommend INCY or IBRX?

Is INCY or IBRX more profitable?

Which has stronger valuation & earnings, INCY or IBRX?

Does the media refer more to INCY or IBRX?

Which has more risk and volatility, INCY or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools